Glasmacinal

The first poster details preclinical data, some of which was produced in collaboration with King’s College London, showing that EP395 is effective in the reduction of eosinophilic inflammation. This, alongside the earlier data on neutrophilic inflammation demonstrates the potential of EP395 as a therapy for COPD patients, irrespective of inflammation subtype. The second poster outlines the clinical data produced from the LPS study of EP395, showing that in healthy, non-smoking, volunteers EP395 treatment increased the host defence response to inhaled LPS, including the epithelial response, whilst inhibiting inflammatory site pro-inflammatory mediators. Lead investigator, Jens Hohlfeld of the Frauenhofer Institute for Toxicology and Experimental Medicine will be presenting the poster alongside the EpiEndo team. A third poster will also present clinical data on the use of EP395 in patients with stable COPD. It showed treatment for three months to be well tolerated, with effects on inflammation and biomarker effects consistent with the variable effects observed in published clinical studies with antimicrobial macrolides in COPD and asthma patients. Lead investigator, Henrik Watz of Velocity Clinical Research will be presenting the poster alongside the EpiEndo team. Both the clinical posters were accepted as late-breaking abstracts to the poster sessions. The details of the abstracts, session times and locations are outlined below. If you would like to meet the EpiEndo team attending the conference, please get in touch. Poster 1 Session 327: Mechanisms underlying asthma pathogenesis and management Abstract PA3922: The new macrolide EP395 reduces eosinophilic inflammation Date: 09/09/2024, 12:30 – 14:00, PS-7 Poster 2 Session 386: New aspects of lung function, inhalers and clinical management for asthma and COPD Abstract PA3922: A novel macrolide, EP395, in LPS challenge in healthy volunteers Date: 10/09/2024, 08:00 - 09:30, PS-10 Poster 3 Session 386: New aspects of lung function, inhalers and clinical management for asthma and COPD Abstract PA3923: A novel macrolide, EP395, in patients with stable COPD: a RCT Date: 10/09/2024, 08:00 - 09:30, PS-10 -ENDS- Contact: EpiEndo Pharmaceuticals: Maria Bech, CEO +354 454 0090­­­ Vigo Consulting (media relations): Rozi Morris +44 20 7390 0230 epiendo@vigoconsulting.com About EpiEndo Pharmaceuticals (www.epiendo.com) EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo’s new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as ‘Barriolides™’, show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). EP395 aims to be the first on-market oral, barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.

REYKJAVIK, ICELAND – 5 June 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has posted a video of CEO Maria Bech speech at BioStock Global Forum from 29th of May. Maria Bech gave a short presentation of EpiEndo and the company's clinical candidate EP395 at BioStock Global Forum on May 29th, 2024. Below you can watch her presentaiton. Contact EpiEndo Pharmaceuticals: Maria Bech, CEO E-mail: maria.bech@epiendo.com Tel: +354 454 0090­­­ About EpiEndo Pharmaceuticals (www.epiendo.com) EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the role of epithelial function in various inflammatory disorders. Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin. EpiEndo’s new class of orally available macrolide, with reduced antimicrobial resistance (AMR) potential, known as ‘Barriolides™’, show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). EP395 aims to be the first on-market oral, barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.